4.7 Article

Preparation of Rh[16aneS4-diol]211At and Ir[16aneS4-diol]211At complexes as potential precursors for astatine radiopharmaceuticals.: Part I:: Synthesis

Journal

BIOCONJUGATE CHEMISTRY
Volume 19, Issue 4, Pages 958-965

Publisher

AMER CHEMICAL SOC
DOI: 10.1021/bc700413r

Keywords

-

Funding

  1. NCI NIH HHS [R01 CA042324, P30 CA014236-35S59008, CA42324, R37 CA042324, P30 CA014236, R37 CA042324-23] Funding Source: Medline
  2. NINDS NIH HHS [P50 NS020023-268624, P50 NS020023] Funding Source: Medline

Ask authors/readers for more resources

The goal of this study was to evaluate a new approach that can be applied for labeling biomolecules with At-211. Many astatine compounds that have been synthesized are unstable in vivo, providing motivation for seeking different At-211 labeling strategies. The approach evaluated in this study was to attach astatide anions to soft metal cations, which are also complexed by a bifunctional ligand. Ultimately, this complex could in principle be subsequently conjugated to a biomolecule with the proper selection of ligand functionality. We report here the attachment of At-211(-) and *I- (*I = I-131 or I-125) anions to the soft metal cations Rh(III) and Ir(III), which are complexed by the 1,5,9,13-tetrathiacyclohexadecane-3,11-diol (16aneS(4)-diol) ligand. Radioactive *I- anions were used for preliminary studies directed at the optimization of reaction conditions and to provide a baseline for comparison of results with At-211. Four complexes Rh[16aneS(4)-diol]*I/At-211 and Ir[16aneS(4)-diol]*I/At-211 were synthesized in high yield in a one-step procedure, and the products were characterized mainly by paper electrophoresis and reversed-phase HPLC. The influences of time and temperature of heating and concentrations of metal cations and sulfur ligand 16aneS(4)-diol, as well as pH on the reaction yields were determined. Yields of about 80% were obtained when the quantities of Rh(III) or Ir(III) cations and 16aneS4-diol ligand in the solutions were 62.5 nmol and 250 nmol, respectively, and the pH ranged 3.0-4.0. Syntheses required heating for 1-1.5 h at 75-80 degrees C. The influence of microwave heating on the time and completeness of the complexation reaction was evaluated and compared with the conventional method of heating in an oil bath. Microwave synthesis accelerates reactions significantly. With microwave heating, yields of about 75% for Rh[16aneS(4)-diol]I-131 and Ir[16aneS(4)-diol]I-131 complexes were obtained after only 20 min exposure of the reaction mixtures to microwave radiation. In conclusion, this study has shown that it is possible to attach an astatide anion to soft metal cations in a simple and fast one-step procedure, with high yields. These complexes will be evaluated as reagents for labeling biomolecules.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Radiology, Nuclear Medicine & Medical Imaging

An Improved 211At-Labeled Agent for PSMA-Targeted α-Therapy

Ronnie C. Mease, Choong Mo Kang, Vivek Kumar, Sangeeta Ray Banerjee, Il Minn, Mary Brummet, Kathleen L. Gabrielson, Yutian Feng, Andrew Park, Ana P. Kiess, George Sgouros, Ganesan Vaidyanathan, Michael R. Zalutsky, Martin G. Pomper

Summary: This study synthesized a new radiotracer, At-211-3-Lu, for the treatment of PSMA-positive prostate cancer. The results showed that At-211-3-Lu had low toxicity, significant therapeutic effects, and no significant off-target toxicity.

JOURNAL OF NUCLEAR MEDICINE (2022)

Article Chemistry, Physical

Crystal Structure, Spectroscopic Characterization, Antioxidant and Cytotoxic Activity of New Mg(II) and Mn(II)/Na(I) Complexes of Isoferulic Acid

Monika Kalinowska, Ewelina Golebiewska, Liliana Mazur, Hanna Lewandowska, Marek Pruszynski, Grzegorz Swiderski, Marta Wyrwas, Natalia Pawluczuk, Wlodzimierz Lewandowski

Summary: The Mg(II) and Mn(II)/Na(I) complexes of isoferulic acid were synthesized and characterized, with the Mg(II) complex showing higher antioxidant activity compared to the ligand alone. On the other hand, the Mn(II)/Na(I) complex exhibited slightly lower activity than the isoferulic acid itself.

MATERIALS (2021)

Article Nanoscience & Nanotechnology

Gold Nanostars: A Novel Platform for Developing 211At-Labeled Agents for Targeted Alpha-Particle Therapy

Yang Liu, Zhengyuan Zhou, Yutian Feng, Xiao-Guang Zhao, Ganesan Vaidyanathan, Michael R. Zalutsky, Tuan Vo-Dinh

Summary: Developing an innovative At-211 nanoplatform with high radiolabeling efficiency and low in vivo deastatination for targeted alpha-particle therapy (TAT) to treat cancer showed promising results. The new platform demonstrated high labeling efficiency, excellent in vivo stability, and significant tumor growth inhibition.

INTERNATIONAL JOURNAL OF NANOMEDICINE (2021)

Article Oncology

The Road to Personalized Myeloma Medicine: Patient-specific Single-domain Antibodies for Anti-idiotypic Radionuclide Therapy

Janik Puttemans, Benoit Stijlemans, Marleen Keyaerts, Sam Vander Meeren, Wim Renmans, Karel Fostier, Pieterjan Debie, Heleen Hanssens, Magdalena Rodak, Marek Pruszynski, Kim De Veirman, Karin Vanderkerken, Tony Lahoutte, Alfred Morgenstern, Frank Bruchertseifer, Nick Devoogdt, Matthias D'Huyvetter

Summary: Multiple myeloma is an incurable cancer, and the lack of effective treatment options has led to disease recurrence. However, patient-specific membrane-expressed paraproteins could hold the key to targeting residual cells responsible for disease recurrence. In this study, radiolabeled anti-idiotypic camelid single-domain antibody fragments (sdAbs) were used as tumor-restrictive vehicles and showed potential for personalized medicine in multiple myeloma patients.

MOLECULAR CANCER THERAPEUTICS (2022)

Review Chemistry, Physical

Nanostructures as Radionuclide Carriers in Auger Electron Therapy

Nasrin Abbasi Gharibkandi, Joanna Gieraltowska, Kamil Wawrowicz, Aleksander Bilewicz

Summary: This review discusses the concept of nanoparticle-mediated radionuclide delivery in cancer treatment and its applications. It presents the development of nanostructures for cancer therapy using Auger electron radionuclides, different types of nanoconstructs as carriers, design principles, nanoparticle materials, and target vectors that overcome challenges. Additionally, systems using high-Z element nanoparticles as radionuclide carriers are discussed.

MATERIALS (2022)

Article Multidisciplinary Sciences

Evaluation of an 131I-labeled HER2-specific single domain antibody fragment for the radiopharmaceutical therapy of HER2-expressing cancers

Yutian Feng, Rebecca Meshaw, Darryl McDougald, Zhengyuan Zhou, Xiao-Guang Zhao, Stephen A. Jannetti, Robert E. Reiman, Erica Pippen, Robin Marjoram, Jeffrey L. Schaal, Ganesan Vaidyanathan, Michael R. Zalutsky

Summary: Radiopharmaceutical therapy has shown promise in the treatment of disseminated cancers, and this study highlights the potential of using HER2-targeted VHH_1028 as a radiopharmaceutical. The results demonstrate that VHH_1028 has higher tumor uptake and lower kidney accumulation compared to the current clinical radiopharmaceutical. Additionally, the use of a solid-phase extraction method for purification of the radiopharmaceutical shows favorable therapeutic effects on tumor growth.

SCIENTIFIC REPORTS (2022)

Article Chemistry, Medicinal

Stapled peptides as scaffolds for developing radiotracers for intracellular targets: Preliminary evaluation of a radioiodinated MDM2-binding stapled peptide in the SJSA-1 osteosarcoma model

Zhengyuan Zhou, Michael R. Zalutsky, Satish K. Chitneni

Summary: Stapled peptide VIP116 has shown potential as a radiolabeled agent targeting MDM2, with high cell uptake and specificity. Tissue distribution studies reveal stable tumor uptake and high tumor-to-muscle ratios, while metabolic stability studies indicate intact activity in plasma. These findings confirm the suitability of VIP116 scaffold for radiolabeled probe development.

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2022)

Article Pharmacology & Pharmacy

Multifunctional Nanoparticles Based on Iron Oxide and Gold-198 Designed for Magnetic Hyperthermia and Radionuclide Therapy as a Potential Tool for Combined HER2-Positive Cancer Treatment

Michal Zuk, Rafal Podgorski, Anna Ruszczynska, Tomasz Ciach, Agnieszka Majkowska-Pilip, Aleksander Bilewicz, Pawel Krysinski

Summary: This study synthesized nanoparticles for multimodal HER2-positive cancer treatment by coating a magnetic core with gold-198 and further modification, achieving targeted therapy effectively. The nanoparticles exhibited good heat mediator properties, specific binding and internalization capabilities towards HER2-positive cancer cells, and degradation ability on tumor spheroids.

PHARMACEUTICS (2022)

Article Chemistry, Physical

Fe(III) and Cu(II) Complexes of Chlorogenic Acid: Spectroscopic, Thermal, Anti-/Pro-Oxidant, and Cytotoxic Studies

Monika Kalinowska, Kamila Gryko, Ewelina Golebiewska, Grzegorz Swiderski, Hanna Lewandowska, Marek Pruszynski, Malgorzata Zawadzka, Maciej Kozlowski, Justyna Sienkiewicz-Gromiuk, Wlodzimierz Lewandowski

Summary: This study synthesized complexes of chlorogenic acid (5-CQA) with copper(II) and iron(III) and analyzed their properties using various methods. The results showed the possible coordination of the complexes through the carboxylate group and the hydroxyl group from the catechol moiety. The complexes exhibited lower antioxidant properties in aqueous solution compared to 5-CQA alone, but showed higher antioxidant activity in the lipid peroxidation inhibition assay. Cu(II) 5-CQA exhibited the highest pro-oxidant activity among the studied compounds. The complexes were not toxic to HaCaT cells within the tested concentration range.

MATERIALS (2022)

Article Engineering, Biomedical

Brachytherapy via a depot of biopolymer-bound 131I synergizes with nanoparticle paclitaxel in therapy-resistant pancreatic tumours

Jeffrey L. Schaal, Jayanta Bhattacharyya, Jeremy Brownstein, Kyle C. Strickland, Garrett Kelly, Soumen Saha, Joshua Milligan, Samagya Banskota, Xinghai Li, Wenge Liu, David G. Kirsch, Michael R. Zalutsky, Ashutosh Chilkoti

Summary: Locally advanced pancreatic tumours that are resistant to conventional radiochemotherapy can be overcome by combining an injectable depot of thermally responsive elastin-like polypeptide with iodine-131 radionuclides and systemically delivered nanoparticle albumin-bound paclitaxel. This combination therapy induces complete tumour regressions in various mouse models of pancreatic tumours. I-131-ELP brachytherapy leads to changes in the expression of intercellular collagen and junctional proteins within the tumour microenvironment, resulting in improved delivery and accumulation of paclitaxel nanoparticles within the tumour.

NATURE BIOMEDICAL ENGINEERING (2022)

Article Chemistry, Medicinal

Site-Specific Radiohalogenation of a HER2-Targeted Single-Domain Antibody Fragment Using a Novel Residualizing Prosthetic Agent

Yutian Feng, Samantha M. Sarrett, Rebecca L. Meshaw, Ganesan Vaidyanathan, Mike A. Cornejo, Brian M. Zeglis, Michael R. Zalutsky

Summary: The study evaluated a new radiotherapeutic vehicle that can accumulate in tumors with high binding affinity and potential therapeutic efficacy for HER2-positive tumor cells.

JOURNAL OF MEDICINAL CHEMISTRY (2022)

Article Biochemistry & Molecular Biology

Doxorubicin- and Trastuzumab-Modified Gold Nanoparticles as Potential Multimodal Agents for Targeted Therapy of HER2+Cancers

Kinga Zelechowska-Matysiak, Kamil Wawrowicz, Mateusz Wierzbicki, Tadeusz Budlewski, Aleksander Bilewicz, Agnieszka Majkowska-Pilip

Summary: In this study, a novel bioconjugate (DOX-AuNPs-Tmab) consisting of gold nanoparticles (AuNPs) attached to chemotherapeutic agent doxorubicin (DOX) and a monoclonal antibody, trastuzumab (Tmab), was synthesized. The bioconjugate exhibited specific binding to HER2 receptors and demonstrated high specificity of binding and internalization capabilities to HER2-positive cancer cells. Cytotoxicity experiments showed that DOX-AuNPs-Tmab significantly reduced cancer cell metabolic activity and surface area of spheroids, inducing cell cycle arrest and late apoptosis. These findings suggest that DOX-AuNPs-Tmab has great potential for targeted therapy of HER2-positive tumors.

MOLECULES (2023)

Review Pharmacology & Pharmacy

DNA Repair Inhibitors: Potential Targets and Partners for Targeted Radionuclide Therapy

Honoka Obata, Mikako Ogawa, Michael R. Zalutsky

Summary: The present review explores potential targets/partners for future targeted radionuclide therapy (TRT) strategies. It discusses key factors in the cancer genome, such as DNA damage response/repair and maintenance systems, that contribute to the survival of cancer cells despite receiving high radiation doses. The review suggests targeting DNA maintenance factors as a promising strategy to enhance the effectiveness of TRT, considering their cancer-specific abilities and dysregulated systems.

PHARMACEUTICS (2023)

Article Radiology, Nuclear Medicine & Medical Imaging

Effective Treatment of Human Breast Carcinoma Xenografts with Single-Dose 211At-Labeled Anti-HER2 Single-Domain Antibody Fragment

Yutian Feng, Rebecca Meshaw, Xiao-Guang Zhao, Stephen Jannetti, Ganesan Vaidyanathan, Michael R. Zalutsky

Summary: This study evaluates the therapeutic potential of single-domain antibody fragments (sdAbs) combined with alpha-particle therapy for HER2-expressing cancers. The results demonstrate that HER2-specific sdAbs, such as 5F7 and VHH_1028, show better efficacy in tumor growth inhibition compared to HER2-irrelevant VHH_2001, suggesting that combining high-affinity HER2-targeted sdAbs with a residualizing prosthetic agent is a promising strategy for targeted alpha-particle therapy.

JOURNAL OF NUCLEAR MEDICINE (2023)

Article Oncology

Low-level whole-brain radiation enhances theranostic potential of single-domain antibody fragments for human epidermal growth factor receptor type 2 (HER2)-positive brain metastases

Daniele Procissi, Stephen A. Jannetti, Markella Zannikou, Zhengyuan Zhou, Darryl McDougald, Deepak Kanojia, Hui Zhang, Kirsten Burdett, Ganesan Vaidyanathan, Michael R. Zalutsky, Irina Balyasnikova

Summary: Low-level brain irradiation induces dynamic changes in tumor vasculature, which increase the delivery of anti-HER2 VHH to intracranial tumors. This finding could facilitate the detection, monitoring, and treatment of HER2-expressing brain metastases.

NEURO-ONCOLOGY ADVANCES (2022)

No Data Available